JewishStatusOpen the app

Jewish News 24 · Oct 22, 2026

Jewish News 24 — photo status

📉 MODERNA STOCK PLUNGES NEARLY 18% AFTER CANCER VACCINE DATA LEAKS EARLY: Moderna shares fell sharply Thursday after results from its experimental personalized mRNA cancer vaccine, developed with Merck, surfaced online ahead of Saturday’s scheduled presentation. According to Reuters and The Wall Street Journal, the Phase 3 trial showed the vaccine, combined with Merck’s Keytruda, reduced the risk of melanoma returning or causing death by 42% and the risk of distant cancer spread or death by 38%, compared with Keytruda alone. Despite the promising findings, shares plunged as the results fell short of investors’ heightened expectations following months of soaring stock prices.

📉 MODERNA STOCK PLUNGES NEARLY 18% AFTER CANCER VACCINE DATA LEAKS EARLY: Moderna shares fell sharply Thursday after results from its experimental personalized mRNA cancer vaccine, developed with Merck, surfaced online ahead of Saturday’s scheduled presentation. According to Reuters and The Wall Street Journal, the Phase 3 trial showed the vaccine, combined with Merck’s Keytruda, reduced the risk of melanoma returning or causing death by 42% and the risk of distant cancer spread or death by 38%, compared with Keytruda alone. Despite the promising findings, shares plunged as the results fell short of investors’ heightened expectations following months of soaring stock prices.

Watch in the app All of Jewish News 24's statuses

More from Jewish News 24